CUE
Cue Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.44
−0.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 37.7M | 27.5M | 9.3M | 5.5M | 1.2M |
| Cost of Revenue | 115.0K | — | — | 38.1M | — |
| Gross Profit | 37.5M | 27.5M | 9.3M | (32.6M) | 1.2M |
| Operating Expenses | |||||
| R&D Expense | 77.1M | 37.7M | 36.3M | 40.8M | 38.6M |
| SG&A Expense | 59.1M | 16.2M | 14.6M | 16.7M | 16.2M |
| General & Admin Expense | 59.1M | 16.2M | 14.6M | 16.7M | 16.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (93.0K) | (37.9M) | (277.0K) |
| Total Operating Expenses | 136.2M | 54.0M | 50.8M | 19.5M | 54.5M |
| Cost and Expenses | 136.3M | 54.0M | 50.8M | 57.6M | 54.5M |
| Operating Income (EBIT) | (98.6M) | (26.5M) | (41.5M) | (52.1M) | (53.2M) |
| Non-Operating | |||||
| Interest Income | 716.0K | 807.0K | 1.6M | 2.7M | 928.2K |
| Interest Expense | 135.0K | 357.0K | 796.0K | 1.2M | 713.8K |
| Net Interest Income | 581.0K | 450.0K | 826.0K | 1.4M | 215.0K |
| Other Non-Op Income/Expense | (65.0M) | 419.0K | 826.0K | 1.4M | 215.0K |
| Non-Operating Income (excl Interest) | (538.0K) | (776.0K) | (1.6M) | (2.7M) | (928.0K) |
| EBT (Pre-Tax Income) | (163.6M) | (26.1M) | (40.7M) | (50.7M) | (53.0M) |
| Income Tax Expense | 500.0K | 500.0K | — | — | — |
| Bottom Line | |||||
| Net Income | (164.1M) | (26.6M) | (40.7M) | (50.7M) | (53.0M) |
| Earnings from Cont. Ops | (164.1M) | (26.6M) | (40.7M) | (50.7M) | (53.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (164.1M) | (26.6M) | (40.7M) | (50.7M) | (53.0M) |
| Per Share | |||||
| Basic EPS | ($26.99) | ($8.40) | ($21.60) | ($33.30) | ($44.70) |
| Diluted EPS | ($27.00) | ($8.40) | ($21.60) | ($33.30) | ($44.70) |
| Revenue Per Share | $5.94 | $8.70 | $4.95 | $3.60 | $1.05 |
| Shares | |||||
| Basic Shares Outstanding | 6.3M | 3.2M | 1.9M | 1.5M | 1.2M |
| Diluted Shares Outstanding | 6.3M | 3.2M | 1.9M | 1.5M | 1.2M |
| Profitability Metrics | |||||
| EBITDA | (95.9M) | (22.3M) | (37.5M) | (46.1M) | (50.5M) |
| D&A | 2.3M | 3.5M | 2.4M | 3.4M | 1.8M |
| EBIT | (98.1M) | (25.7M) | (39.9M) | (49.5M) | (52.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026